An experimental Covid-19 vaccine developed by Britain's GlaxoSmithKline and Sanofi has been found to show an 'insufficient immune response' in clinical trial results, in a blow to efforts to fight the pandemic.
The two companies said they planned to launch another study next year, hoping to come up with a more effective vaccine by the end of 2021.
The results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years, but a low immune response in older adults.
Thomas Triomphe, Executive Vice President and Head of Sanofi Pasteur, said: “We care greatly about public health which is why we are disappointed by the delay announced today, but all our decisions are and will always be driven by